Oral Pathogen Proteases Rewire the Renin–Angiotensin System: Direct Generation of Angiotensin (1-7)

Study Background and Research Question

The renin–angiotensin system (RAS) orchestrates essential physiological processes, including blood pressure regulation, electrolyte balance, and tissue inflammation. Traditionally, RAS activity is considered the domain of host enzymes, wherein angiotensinogen is cleaved by renin to angiotensin I (Ang I), and subsequently processed to angiotensin II (Ang II)—a vasoconstrictive, proinflammatory peptide—or to Angiotensin (1-7) [Asp-Arg-Val-Tyr-Ile-His-Pro], a Mas receptor agonist with anti-inflammatory, vasodilatory, and anti-fibrotic properties. The balance between Ang II and Ang-(1-7) is central to cardiovascular and metabolic health. Recent clinical and epidemiological data suggest that periodontal disease, driven by oral pathogen overgrowth, correlates with systemic conditions such as hypertension, diabetes, and cardiovascular disease. However, the precise molecular mechanisms linking oral dysbiosis to systemic RAS modulation remain incompletely understood. The current study, Periodontopathogens degrade angiotensin I from the human renin–angiotensin system through surface-attached proteases, addresses whether periodontopathogens directly influence RAS peptide processing within the oral environment.

Key Innovation from the Reference Study

This work uncovers a previously unrecognized pathway: specific oral pathogens can directly generate Angiotensin (1-7) from Ang I via specialized surface-bound proteases, without reliance on host-derived angiotensin-converting enzymes. Porphyromonas gingivalis (Pg) and Tannerella forsythia (Tf), both members of the "red complex" implicated in severe periodontitis, express endopeptidases—PgPepO and TfPepO—that catalyze the conversion of Ang I to Ang-(1-7). Notably, this microbial pathway may locally enhance anti-inflammatory Ang-(1-7) formation, potentially rebalancing RAS activity in the oral microenvironment and systemically.

Methods and Experimental Design Insights

The investigators combined biochemical, structural, and in vivo approaches to elucidate this phenomenon. Key methods included:

• Peptide hydrolysis assays: Synthetic Ang I was incubated with purified Pg and Tf proteases, and peptide fragments were analyzed by mass spectrometry to confirm the generation of Ang-(1-7).
• Protease characterization: Both PgPepO and TfPepO were assessed for substrate specificity. Structural studies via X-ray crystallography revealed broad catalytic clefts in these metalloproteases, rationalizing their ability to accommodate Ang I and release Ang-(1-7).
• Cell-surface localization and vesicle release: Immunoassays demonstrated that PepOs are anchored to bacterial surfaces and are also released in outer membrane vesicles, increasing their dispersal potential.
• Genetic deletion and virulence modeling: Deletion mutants lacking PepO in Pg and Tf were constructed, and their impact on Ang I hydrolysis and virulence was assessed using the Galleria mellonella model.

Core Findings and Why They Matter

The study’s central finding is that Pg and Tf are capable of directly converting Ang I to Angiotensin (1-7) through their surface metalloproteases. This bypasses canonical host enzymatic pathways (ACE and ACE2) and represents a microbe-driven modulation of a major human hormonal axis. Several mechanistic insights emerged:

• PepO proteases show a preference for cleaving substrates with large hydrophobic amino acids at the P1’ position, aligning with Ang I’s sequence requirements for Ang-(1-7) release.
• TfPepO is structurally unique among homologous proteases, with a wider catalytic cleft, facilitating its ability to hydrolyze peptide bonds distant from either terminus, a key adaptation for Ang-(1-7) generation.
• The release of PepOs in membrane vesicles suggests the potential for broader dissemination of this enzymatic activity within the oral cavity.
• Importantly, deletion of PepO reduced the virulence of Tf (but not Pg) in the invertebrate infection model, supporting the role of this enzyme in both peptide processing and microbial pathogenicity.

These findings suggest that periodontopathogen-driven local RAS modulation could attenuate, or conversely, dysregulate inflammation and tissue responses in periodontal disease. The direct microbial generation of Angiotensin (1-7), known for its anti-fibrotic and anti-inflammatory effects, introduces a new dimension to the oral-systemic health connection.

Comparison with Existing Internal Articles

Previous internal reviews have highlighted the physiological and experimental significance of Angiotensin (1-7):

• "Periodontopathogen Proteases Redirect RAS to Angiotensin (1-7) Formation" first summarized the observation that oral bacteria can facilitate Ang-(1-7) generation, but the present study provides structural and genetic evidence for the exclusive role of PepO proteases in this process.
• "Angiotensin (1-7): Mechanistic Insights and Experimental..." focuses on the peptide's signaling properties—such as PI3K/AKT and ERK pathway modulation—and its roles as an anti-inflammatory agent. The current reference paper connects these molecular effects to the oral microbiome’s capacity to regulate Ang-(1-7) availability.
• "Applied Workflows for Angiotensin (1-7): Bench to Translation" offers practical guidance for experimental studies utilizing Ang-(1-7), which is directly relevant for researchers seeking to model oral or systemic RAS modulation in vitro or in vivo.

This reference study thus bridges microbiology, structural biology, and hormone signaling, illuminating a cross-domain pathway from oral infection to systemic peptide regulation.

Limitations and Transferability

While the study provides clear mechanistic evidence for PepO-mediated Ang-(1-7) generation, several limitations should be noted:

• Most experiments utilized in vitro peptide cleavage assays or invertebrate infection models, which may not fully recapitulate the complexity of human oral and systemic environments.
• Although Ang-(1-7) formation was demonstrated, the in vivo functional consequences—such as modulation of local inflammation, systemic blood pressure, or metabolic outcomes—require further validation in mammalian models.
• The study centered on two periodontopathogens; whether similar mechanisms operate in other oral or extraoral microbiomes remains to be determined.

Nonetheless, the demonstration of a direct, pathogen-catalyzed RAS axis provides a strong rationale for future translational research linking oral health to systemic disease via peptide hormone modulation.

Protocol Parameters

• Angiotensin I substrate incubation: Incubate synthetic Ang I (human sequence) with purified PepO proteases under physiological pH and ionic conditions; optimal cleavage observed at 37°C for 1-2 hours.
• Protease detection: Use immunoassays to confirm surface localization of PepO on periodontopathogen cell envelopes and in isolated membrane vesicles.
• Mutant strain analysis: Construct and compare wild-type vs. PepO-deficient bacterial strains for Ang I hydrolysis efficiency and in vivo virulence in Galleria mellonella models.
• Angiotensin (1-7) detection: Quantify released Ang-(1-7) using mass spectrometry or targeted immunoassays following protease incubation.

Why this cross-domain matters, maturity, and limitations

The evidence that oral pathogens can generate Angiotensin (1-7) expands the conceptual framework for the oral-systemic health axis. This mechanism suggests that microbial communities may actively modulate host signaling peptides, potentially influencing inflammation, tissue repair, and vascular homeostasis beyond the oral cavity. While the structural and genetic data are robust, functional studies in mammalian models and clinical cohorts remain necessary to translate these molecular insights into therapeutic or diagnostic advances.

Research Support Resources

To experimentally investigate RAS modulation or to model Angiotensin (1-7)-dependent signaling—such as PI3K/AKT and ERK pathway regulation—researchers may utilize high-purity Angiotensin (1-7) (Asp-Arg-Val-Tyr-Ile-His-Pro). The Angiotensin (1-7) peptide (SKU A1041, APExBIO) offers validated solubility in water and DMSO and is suitable for both in vitro and in vivo applications, including studies on anti-fibrotic and anti-inflammatory mechanisms. For further protocol guidance and mechanistic context, refer to the internal article "Applied Workflows for Angiotensin (1-7): Bench to Translation".